Mirikizumab (Omvoh™) for ulcerative colitis

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Mirikizumab (Omvoh™) for ulcerative colitis. / Hammerhøj, Alexander; Boye, Theresa Louise; Langholz, Ebbe; Nielsen, Ole Haagen.

In: Trends in Pharmacological Sciences, Vol. 45, No. 3, 2024, p. 281-282.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Hammerhøj, A, Boye, TL, Langholz, E & Nielsen, OH 2024, 'Mirikizumab (Omvoh™) for ulcerative colitis', Trends in Pharmacological Sciences, vol. 45, no. 3, pp. 281-282. https://doi.org/10.1016/j.tips.2024.01.001

APA

Hammerhøj, A., Boye, T. L., Langholz, E., & Nielsen, O. H. (2024). Mirikizumab (Omvoh™) for ulcerative colitis. Trends in Pharmacological Sciences, 45(3), 281-282. https://doi.org/10.1016/j.tips.2024.01.001

Vancouver

Hammerhøj A, Boye TL, Langholz E, Nielsen OH. Mirikizumab (Omvoh™) for ulcerative colitis. Trends in Pharmacological Sciences. 2024;45(3):281-282. https://doi.org/10.1016/j.tips.2024.01.001

Author

Hammerhøj, Alexander ; Boye, Theresa Louise ; Langholz, Ebbe ; Nielsen, Ole Haagen. / Mirikizumab (Omvoh™) for ulcerative colitis. In: Trends in Pharmacological Sciences. 2024 ; Vol. 45, No. 3. pp. 281-282.

Bibtex

@article{3ffc8410b2c043c4bd8379ddb0befeee,
title = "Mirikizumab (Omvoh{\texttrademark}) for ulcerative colitis",
abstract = "STRUCTURE: Mirikizumab is a humanized IgG4-variant monoclonal antibody consisting of two heavy-chain and two light-chain subunits. Mirikizumab binds with high affinity to the p19 subunit (α subunit) of the heterodimeric interleukin-23 (IL-23).",
author = "Alexander Hammerh{\o}j and Boye, {Theresa Louise} and Ebbe Langholz and Nielsen, {Ole Haagen}",
year = "2024",
doi = "10.1016/j.tips.2024.01.001",
language = "English",
volume = "45",
pages = "281--282",
journal = "Trends in Pharmacological Sciences",
issn = "0165-6147",
publisher = "Elsevier Ltd. * Trends Journals",
number = "3",

}

RIS

TY - JOUR

T1 - Mirikizumab (Omvoh™) for ulcerative colitis

AU - Hammerhøj, Alexander

AU - Boye, Theresa Louise

AU - Langholz, Ebbe

AU - Nielsen, Ole Haagen

PY - 2024

Y1 - 2024

N2 - STRUCTURE: Mirikizumab is a humanized IgG4-variant monoclonal antibody consisting of two heavy-chain and two light-chain subunits. Mirikizumab binds with high affinity to the p19 subunit (α subunit) of the heterodimeric interleukin-23 (IL-23).

AB - STRUCTURE: Mirikizumab is a humanized IgG4-variant monoclonal antibody consisting of two heavy-chain and two light-chain subunits. Mirikizumab binds with high affinity to the p19 subunit (α subunit) of the heterodimeric interleukin-23 (IL-23).

U2 - 10.1016/j.tips.2024.01.001

DO - 10.1016/j.tips.2024.01.001

M3 - Journal article

C2 - 38262797

VL - 45

SP - 281

EP - 282

JO - Trends in Pharmacological Sciences

JF - Trends in Pharmacological Sciences

SN - 0165-6147

IS - 3

ER -

ID: 380697148